Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial

Date
2018
Author
LIN, Chinjune
Ozguroglu, Mustafa
RIDOLFI, Antonia
CARDOSO, Fatima
Royce, Melanie
BACHELOT, Thomas
VILLANUEVA, Cristian
AZEVEDO, Sergio J.
CRUZ, Felipe Melo
DEBLED, Marc
Hegg, Roberto
TOYAMA, Tatsuya
FALKSON, Carla
JEONG, Joon
SRIMUNINNIMIT, Vichien
Gradishar, William J.
ARCE, Christina
Metadata
Show full item record
Abstract
IMPORTANCE Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer.
URI
http://hdl.handle.net/20.500.12627/49403
https://doi.org/10.1001/jamaoncol.2018.0060
Collections